Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario.
BACKGROUND
Several DNA mismatch repair (MMR) genes, responsible for the majority of Lynch Syndrome cancers, have been identified, predominantly MLH1 and MSH2, but the risk associated with these mutations is still not well established. The aim of this study is to provide population-based estimates of the risks of colorectal cancer (CRC) by gender and mutation type from the Ontario population.


METHODS
We analyzed 32 families segregating MMR mutations selected from the Ontario Familial Colorectal Cancer Registry and including 199 first-degree and 421 second-degree relatives. The cumulative risks were estimated using a modified segregation-based approach, which allows correction for the ascertainment of the Lynch Syndrome families and permits account to be taken for missing genotype information.


RESULTS
The risks of developing CRC by age 70 were 60% and 47% among men and women carriers of any MMR mutation, respectively. Among MLH1 mutation carriers, males had significantly higher risks than females at all ages (67% vs. 35% by age 70, p-value = 0.02), while the risks were similar in MSH2 carriers (about 54%). The relative risk associated with MLH1 was almost constant with age (hazard ratio (HR) varied between 5.5-5.1 over age 30-70), while the HR for MSH2 decreased with age (from 13.1 at age 30 to 5.4 at age 70).


CONCLUSIONS
This study provides a unique population-based study of CRC risks among MSH2/MLH1 mutation carriers in a Canadian population and can help to better define and understand the patterns of risks among members of Lynch Syndrome families.
Choi
Yun-Hee
YH
Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Toronto, Canada. Yun-Hee.Choi@schulich.uwo.ca
Cotterchio
Michelle
M
McKeown-Eyssen
Gail
G
Neerav
Monga
M
Bapat
Bharati
B
Boyd
Kevin
K
Gallinger
Steven
S
McLaughlin
John
J
Aronson
Melyssa
M
Briollais
Laurent
L
Genet Epidemiol. 2005 Jul;29(1):36-50
15834862
J Med Genet. 2003 Mar;40(3):208-13
12624141
Nucleic Acids Res. 2002 Jun 15;30(12):e57
12060695
Hum Mol Genet. 1997 Jan;6(1):105-10
9002677
Nucleic Acids Res. 2002 Sep 1;30(17):3894-900
12202775
J Gastrointest Surg. 1998 Jan-Feb;2(1):67-71
9841970
Int J Cancer. 1999 Apr 12;81(2):214-8
10188721
Genome Res. 2001 May;11(5):863-74
11337480
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6853-61
16203774
Gastroenterology. 1999 Jun;116(6):1453-6
10348829
J Clin Oncol. 2001 Oct 15;19(20):4074-80
11600610
Eur J Cancer Prev. 1994 Jul;3(4):321-7
7950886
Chronic Dis Can. 2000;21(2):81-6
11007659
Cancer Res. 1998 Nov 15;58(22):5248-57
9823339
Hum Genet. 1999 Feb;104(2):167-76
10190329
Biochim Biophys Acta. 1999 May 31;1423(3):O1-O10
10382540
Am J Hum Genet. 2000 Mar;66(3):1119-31
10712222
Dis Colon Rectum. 2002 Sep;45(9):1223-32
12352241
Gastroenterology. 2005 Aug;129(2):415-21
16083698
Genet Epidemiol. 2004 Sep;27(2):109-17
15305327
J Med Genet. 2005 Jun;42(6):491-6
15937084
Hum Hered. 2008;66(4):238-51
18612208
Gastroenterology. 1996 Apr;110(4):1020-7
8612988
Br J Cancer. 2000 Dec;83(12):1643-5
11104559
J Natl Cancer Inst. 2002 Aug 21;94(16):1221-6
12189225
J Med Genet. 1999 Feb;36(2):97-102
10051005
Int J Cancer. 1995 Dec 20;64(6):430-3
8550246
Cancer. 1999 Dec 1;86(11 Suppl):2457-63
10630171
Clin Gastroenterol Hepatol. 2006 Apr;4(4):489-98
16616355